CHRS vs MSFT: Which Stock is Better?
Side-by-side comparison of Coherus Oncology Inc and Microsoft Corp in 2026
CHRS
Coherus Oncology Inc
$1.99
MSFT
Microsoft Corp
$417.51
Key Metrics Comparison
| Metric | CHRS | MSFT | Winner |
|---|---|---|---|
| Market Cap | $296.78M | N/A | CHRS |
| P/E Ratio | N/A | 26.46 | MSFT |
| EPS (TTM) | $N/A | $15.98 | MSFT |
| Revenue Growth | 0.6% | 0.2% | CHRS |
| Gross Margin | 67.2% | 68.6% | MSFT |
Analyze CHRS
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is CHRS or MSFT a better investment?
Comparing CHRS and MSFT: Coherus Oncology Inc has a market cap of $296.78M while Microsoft Corp has N/A. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between CHRS and MSFT?
CHRS (Coherus Oncology Inc) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: CHRS or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: CHRS or MSFT?
CHRS has higher revenue growth at 0.6% vs 0.2% for MSFT.
Which company is more profitable: CHRS or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.6% compared to 67.2% for CHRS.
Which is the larger company: CHRS or MSFT?
Coherus Oncology Inc (CHRS) is larger with a market cap of $296.78M compared to N/A for MSFT.
Should I buy CHRS or MSFT in 2026?
Both CHRS and MSFT have investment merit. CHRS trades at $1.99 while MSFT trades at $417.51. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between CHRS and MSFT stock?
Key differences: Market Cap ($296.78M vs N/A), P/E Ratio (N/A vs 26.5x), Revenue Growth (0.6% vs 0.2%), Gross Margin (67.2% vs 68.6%).